Gail Risbridger

Abstract 2155: PMR-116, a novel inhibitor of ribosome biogenesis with antitumor activity in preclinical models of prostate cancer

Alisee Huglo, Richard Rebello, Mitchell Lawrence, Gail Risbridger, Denis Drygin, Mustapha Haddach, Katherine Hannan, Ross Hannan, Luc Furic

Conference Proceedings  |  2022  |  Cancer Research

Abstract Advanced prostate cancer is characterised by mutations and amplifications of genes involved in regulating ..

OCT1-target neural gene PFN2 promotes tumor growth in androgen receptor-negative prostate cancer

Daisuke Obinata, Daigo Funakoshi, Kenichi Takayama, Makoto Hara, Birunthi Niranjan, Linda Teng, Mitchell G Lawrence, Renea A Taylor, Gail P Risbridger, Yutaka Suzuki, Satoru Takahashi, Satoshi Inoue

Journal article  |  2022  |  SCIENTIFIC REPORTS

Androgen and androgen receptor (AR) targeted therapies are the main treatment for most prostate cancer (PC) patients. Although AR ..

Identification of OCT1 target genes involved in progression of castration-resistant AR-null prostate cancer

Daisuke Obinata, Kenichi Takayama, Daigo Funakoshi, Mitchell Lawrence, Renea Taylor, Shahneen Sandhu, Gail Risbridger

Conference Proceedings  |  2022  |  CANCER SCIENCE

Chimeric Antigen Receptor T-Cell Therapy in Metastatic Castrate-Resistant Prostate Cancer

Mahasha PJ Perera, Patrick B Thomas, Gail P Risbridger, Renea Taylor, Arun Azad, Michael S Hofman, Elizabeth D Williams, Ian Vela

Journal article  |  2022  |  CANCERS

Prostate cancer is the most commonly diagnosed solid-organ cancer amongst males worldwide. Metastatic castrate-resistant prostate ..

Colorimetric Detection of Extracellular Hydrogen Peroxide Using an Integrated Microfluidic Device

Esma Dervisevic, Nicolas H Voelcker, Gail Risbridger, Kellie L Tuck, Victor J Cadarso

Journal article  |  2022  |  ANALYTICAL CHEMISTRY

It is well known that hydrogen peroxide (H2O2) is a signaling molecule essential for vital physiological reactions in mammalian ce..

Neuroendocrine cells in prostate cancer correlate with poor outcomes: a systematic review and meta-analysis

Ashwini Kannan, David Clouston, Mark Frydenberg, Dragan Ilic, Md Nazmul Karim, Sue M Evans, Roxanne Toivanen, Gail P Risbridger, Renea A Taylor

Journal article  |  2021  |  BJU INTERNATIONAL

OBJECTIVES: To perform a systematic review and meta-analysis of the literature to understand the variation in the reporting of neu..

CX-5461 Sensitizes DNA Damage Repair-proficient Castrate-resistant Prostate Cancer to PARP Inhibition

Mitchell G Lawrence, Laura H Porter, Nicholas Choo, David Pook, Jeremy P Grummet, Carmel J Pezaro, Shahneen Sandhu, Susanne Ramm, Jennii Luu, Andrew Bakshi, David L Goode, Elaine Sanij, Richard B Pearson, Ross D Hannan, Kaylene J Simpson, Renea A Taylor, Gail P Risbridger, Luc Furic

Journal article  |  2021  |  MOLECULAR CANCER THERAPEUTICS

Monotherapy with PARP inhibitors is effective for the subset of castrate-resistant prostate cancer (CRPC) with defects in homologo..

Hidden clues in prostate cancer-Lessons learned from clinical and pre-clinical approaches on diagnosis and risk stratification

Roxanne Toivanen, Laura H Porter, Zhuoer Li, David Clouston, Gail P Risbridger, Renea A Taylor

Journal article  |  2021  |  CANCER LETTERS

The heterogeneity of prostate cancer is evident at clinical, morphological and molecular levels. To aid clinical decision making, ..

A humanized orthotopic tumor microenvironment alters the bone metastatic tropism of prostate cancer cells.

Jacqui A McGovern, Nathalie Bock, Abbas Shafiee, Laure C Martine, Ferdinand Wagner, Jeremy G Baldwin, Marietta Landgraf, Christoph A Lahr, Christoph Meinert, Elizabeth D Williams, Pamela M Pollock, Jim Denham, Pamela J Russell, Gail P Risbridger, Judith A Clements, Daniela Loessner, Boris M Holzapfel, Dietmar W Hutmacher

Journal article  |  2021  |  Commun Biol

Prostate cancer (PCa) is the second most commonly diagnosed cancer in men, and bone is the most frequent site of metastasis. The t..

The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology

Gail P Risbridger, Ashlee K Clark, Laura H Porter, Roxanne Toivanen, Andrew Bakshi, Natalie L Lister, David Pook, Carmel J Pezaro, Shahneen Sandhu, Shivakumar Keerthikumar, Rosalia Quezada Urban, Melissa Papargiris, Jenna Kraska, Heather B Madsen, Hong Wang, Michelle G Richards, Birunthi Niranjan, Samantha O'Dea, Linda Teng, William Wheelahan, et al.

Journal article  |  2021  |  NATURE COMMUNICATIONS

Preclinical testing is a crucial step in evaluating cancer therapeutics. We aimed to establish a significant resource of patient-d..